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Results: Patient characteristics are shown in Table 1 and FFF 
in Figure 1. FFF at 4y was 77 % in cohort A versus 55 % in 
cohort B (Fig 1-L, p=0.02). Adjuvant hormonal treatment 
(AHT) prescription was mainly based on pre-MR findings in 
Cohort A, and introduced for high-risk patients during the 
recruitment period of cohort B. As a result, more patients in 
Cohort A received AHT (p<0.01). Although in both cohorts the 
maximum age was around 80 years, Cohort A contained more 
older patients (p<0.01) and also more aggressive tumors 
(p<0.01). Low/intermediate risk patients with 0-6m AHT, had 
worse FFF < 5.5y (p=0.04) compared to high-risk with 3 AHT 
in cohort A (Fig 1-R). The corresponding 
FF
  
 
 
Conclusions: There was no significant cohort effect at MV 
analysis, suggesting that the observed difference in FFF is 
mainly caused by AHT prescription, implying that MR-T3b 
tumors show similar aggressive disease as clinically 
determined T3b tumors. In line with this, the results also 
suggest that long-term AHT might also be beneficial for MR-
T3b patients with otherwise low-intermediate risk features.  
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Purpose/Objective: Hyperthermia (HT) is a (neo)adjuvant 
treatment modality that increases the effectiveness of 
radiotherapy or chemotherapy by heating the tumour area to 
41–43 °C. Recently a multi-centre phase III randomized 
clinical trial comparing adjuvant treatment of non-muscle 
invasive bladder cancer (NMIBC) using Mytomycin C (MMC) 
with and without loco-regional HT has started. 
A good clinical effect requires a well-controlled thermal 
dose, as treatment outcome is temperature dependent. This 
necessitates reliable thermometry and detailed 
thermophysical fluid models to accurately monitor and 
predict the temperature distribution inside the bladder and 
bladder wall. Recently, we presented the 'umbrella' probe, a 
novel multi-sensor temperature probe that accurately 
measures the temperature of both the bladder wall and the 
fluid inside. However, detailed thermophysical fluid models 
are still lacking in the present, in-house developed HT 
Treatment Planning System (HTPS). 
This study's final goal is to optimize the temperature 
distribution and registration during HT bladder treatment 
using 3D steering of the power deposition. To this end we are 
developing a high resolution HTPS capable of modelling 
convective heat transport inside the bladder. 
Materials and Methods: We created a convective thermal 
model and set up a phantom experiment to test its accuracy. 
A porcine bladder filled with 60 ml 0.9 % NaCl solution was 
placed in tissue equivalent gel. The phantom was heated 
with the AMC-4 deep HT device for 900 s at 400 W to reach a 
clinical temperature rise. This was repeated with 120 ml 
saline solution to cover the clinically relevant volume range. 
Inside the bladder, temperatures were measured using the 
umbrella probe, on the outside we used copper-constantan 
thermocouple probes. We simulated this experiment using 
both the current HTPS and the new convective model using 
the OpenFOAM toolkit. Both were compared to the 
measurements. 
Results: The temperature distribution computed by the 
convective model was in much closer agreement with the 
measurements in and around the bladder than that by 
current HTPS. The temperature measurements in the 60 ml 
case are practically identical to that in the 120 ml case. 
Comparison of the temperature distribution between the new 
convective model and the current HTPS showed good 
agreement within the solid regions of the phantom; however, 
both models differed significantly inside the fluid and in the 
immediately surrounding tissue, i.c. the bladder wall (Figure 
1). This range of temperature differences exceeded 1 °C in 
either direction, demonstrating the need for the new model. 
The current HTPS generally underestimated the bladder wall 
temperature and overestimated the temperature at the 
bladder centre. 
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Conclusions: The new convective model is a marked 
improvement over the current HTPS. Explicit modelling of 
fluids is particularly important when the bladder or its direct 
surroundings are part of the treatment target area. 
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Purpose/Objective: The prognosis of patients with high risk 
prostate cancer (PCa) is improved by adjuvant radiotherapy 
(RT) after radical prostatectomy (RP), although the 5 year 
biochemical recurrence free survival (bRFS) does not exceed 
75-80%. Hypofractionated RT allows shorter treatment time 
and is theoretically associated with an improvement in the 
probability of cure in patients with PCa. However, 
hypofractionated RT may be associated with a higher 
incidence of long-term advers effects. To date, definitive 
indications on safety and efficacy of this fractionation are 
not available, especially in patients undergoing RP. 
Therefore, aim of this study was to evaluate safety and 
efficacy of postoperative hypofractionated RT with based on 
SIB-IMRT technique. 
Materials and Methods: Patients with high-risk resected PCa 
(R1, pT3, Gleason Score > 7) were enrolled in the study. The 
dose to the prostate was 62.5 Gy (2.5 Gy / fraction). In 
patients with dissection of < 7 lymph nodes and with a risk of 
nodal involvement > 15%, prophylactic irradiation of pelvic 
lymph nodes was performed. Furthermore, according to the 
NCCN risk categories, adjuvant hormone therapy (HT) was 
prescribed (intermediate risk: 6 months; high risk: 24 
months); bRFS (PSA> 0.2 ng/ml), local control, disease-free 
and overall survival were assessed using the Kaplan-Meier 
method. Survival curves were compared by log-rank test 
(univariate analysis) and Cox Proportional Hazard Method 
(multivariate analysis, considering as covariates: stage, 
pretreatment PSA, Gleason Score, RT treatment modalities, 
HT duration). Patients were classified according to the NCCN 
2014 risk categories. 
Results: A total of 127 patients were enrolled in the study 
(R1: 83.3%, pT3-4: 81.6%, Gleason score > 7: 38.9%). The 
results of the analysis are shown in the table.  
 
Conclusions: In a phase I-II study on postoperative 
hypofractionated-accelerated RT plus HT based on risk 
factors, an acceptable incidence of acute and long-term side 
effects and an improved bRFS compared to standard 
postoperative RT were recorded. 
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Purpose/Objective: Recent studies have expanded the 
concept that the systemic inflammatory response has an 
important role in the progression of several solid tumours. 
The neutrophil-to-lymphocyte ratio (NLR), an easily 
determinable marker of systemic inflammation, has been 
associated with clinical outcome in various cancer entities. In 
the present study, we validated the prognostic relevance of 
an elevated pre-treatment NLR in a cohort of European 
patients with non-metastatic prostate cancer treated with 3D 
conformal radiotherapy. 
Materials and Methods: Data from 415 consecutive non-
metastatic prostate cancer patients treated with 3D 
conformal radiotherapy at a single tertiary academic center 
from 1999-2007 were included in this retrospective study. 
Clinical disease-free survival (DFS), distant metastases-free 
survival (DMFS), and overall survival (OS) were assessed using 
the Kaplan-Meier method. To evaluate the prognostic 
relevance, univariate and multivariate Cox regression models 
were performed for each endpoint.  
Results: Based on previous studies, an NLR cut-off value of 5 
was applied to differentiate between a low (<5) and high (≥5) 
NLR.  
In univariate analysis, the elevated NLR was significantly 
associated with decreased clinical PFS (HR 1.87, 95% CI 1.05-
3.32, p=0.033) that remained significant in the multivariate 
analysis (HR 2.53, 95%CI 1.40-4.59, p=0.002). Additionally, 
